Loading…
Pregnancy Outcomes Following Use of Escitalopram: A Prospective Comparative Cohort Study
Escitalopram is a serotonin reuptake inhibitor prescribed for depression and anxiety. There is a paucity of information regarding safety in pregnancy. The objective of this study was to determine whether escitalopram is associated with an increased risk for major malformations or other adverse outco...
Saved in:
| Published in: | Journal of clinical pharmacology 2012-05, Vol.52 (5), p.766-770 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4954-11e728be071b2d3573182aa76c67314d2a69c55953cf23cd797ac51c7e9ffe5f3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4954-11e728be071b2d3573182aa76c67314d2a69c55953cf23cd797ac51c7e9ffe5f3 |
| container_end_page | 770 |
| container_issue | 5 |
| container_start_page | 766 |
| container_title | Journal of clinical pharmacology |
| container_volume | 52 |
| creator | Klieger-Grossmann, Chagit Weitzner, Brenda Panchaud, Alice Pistelli, Alessandra Einarson, Thomas Koren, Gideon Einarson, Adrienne |
| description | Escitalopram is a serotonin reuptake inhibitor prescribed for depression and anxiety. There is a paucity of information regarding safety in pregnancy. The objective of this study was to determine whether escitalopram is associated with an increased risk for major malformations or other adverse outcomes following use in pregnancy. The authors analyzed pregnancy outcomes in women exposed to escitalopram (n = 212) versus other antidepressants (n = 212) versus nonteratogenic exposures (n = 212) and compared the outcomes. Among the escitalopram exposures were 172 (81%) live births, 32 (15%) spontaneous abortions, 6 (2.8%) therapeutic abortions, 3 stillbirths (1.7%), and 3 major malformations (1.7%). The only significant differences among groups was the rate of low birth weight ( |
| doi_str_mv | 10.1177/0091270011405524 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1010231340</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0091270011405524</sage_id><sourcerecordid>1010231340</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4954-11e728be071b2d3573182aa76c67314d2a69c55953cf23cd797ac51c7e9ffe5f3</originalsourceid><addsrcrecordid>eNqFUE1v1DAQtRAV3RbunFAkLlxCPY4dN9yqVbcFKrp8VHCzvM5kN60TBzvpsv8eRxsqVAlxsGasee_NvEfIS6BvAaQ8obQAJikF4FQIxp-QGcSa8pzyp2Q2jtNxfkiOQriNuJwLeEYOGaNSsIzNyI-lx3WrW7NLrofeuAZDsnDWum3drpObgImrkvNg6l5b13ndvEvOkqV3oUPT1_eYzF3Taa-nfuN8n3zth3L3nBxU2gZ8MdVjcrM4_za_TK-uL97Pz65SwwvBUwCU7HSFVMKKlZmQGZwyrWVu8tjykum8MEIUIjMVy0wpC6mNACOxqCoUVXZM3ux1O-9-Dhh61dTBoLW6RTcEBRQoyyDjNEJfP4LeusG38ToFksZ9jBd5RNE9ykSXwWOlOl832u-ilBpTV49Tj5RXk_CwarB8IPyJOQL4HrB1tkcf7uywRa82qG2_iXqU8qiXMgqMivhL44NRN59otcXdf-9QH-bLSyFg9JDuiUGv8S-X_zYw4evQ46-HRdrfqRiLFOr7pwv1ETj7zL4sFM9-A-q4tWg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1706732496</pqid></control><display><type>article</type><title>Pregnancy Outcomes Following Use of Escitalopram: A Prospective Comparative Cohort Study</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Klieger-Grossmann, Chagit ; Weitzner, Brenda ; Panchaud, Alice ; Pistelli, Alessandra ; Einarson, Thomas ; Koren, Gideon ; Einarson, Adrienne</creator><creatorcontrib>Klieger-Grossmann, Chagit ; Weitzner, Brenda ; Panchaud, Alice ; Pistelli, Alessandra ; Einarson, Thomas ; Koren, Gideon ; Einarson, Adrienne</creatorcontrib><description>Escitalopram is a serotonin reuptake inhibitor prescribed for depression and anxiety. There is a paucity of information regarding safety in pregnancy. The objective of this study was to determine whether escitalopram is associated with an increased risk for major malformations or other adverse outcomes following use in pregnancy. The authors analyzed pregnancy outcomes in women exposed to escitalopram (n = 212) versus other antidepressants (n = 212) versus nonteratogenic exposures (n = 212) and compared the outcomes. Among the escitalopram exposures were 172 (81%) live births, 32 (15%) spontaneous abortions, 6 (2.8%) therapeutic abortions, 3 stillbirths (1.7%), and 3 major malformations (1.7%). The only significant differences among groups was the rate of low birth weight (<2500 g) and overall mean birth weight (P = .225). However, spontaneous abortion rates were higher in both antidepressant groups (15% and 16%) compared with controls (8.5%; P = .066). There were lower rates of live births (P = .006), lower overall birth weight (P < .001), and increased rates of low birth weight (<2500 g; P = .009) with escitalopram. Spontaneous abortion rates were nearly double in both antidepressant groups (15% and 16%) compared with controls (8.5%) but not significant (P = .066). Escitalopram does not appear to be associated with an increased risk for major malformations but appears to increase the risk for low birth weight, which was correlated with the increase in infants weighing <2500 g. In addition, the higher rates of spontaneous abortions in both antidepressant groups confirmed previous findings.</description><identifier>ISSN: 0091-2700</identifier><identifier>EISSN: 1552-4604</identifier><identifier>DOI: 10.1177/0091270011405524</identifier><identifier>PMID: 22075232</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Abnormalities, Drug-Induced - etiology ; Abortion ; Abortion, Spontaneous - chemically induced ; Abortion, Therapeutic ; Analysis of Variance ; Antidepressants ; Antidepressive Agents, Second-Generation - adverse effects ; Birth weight ; Birth Weight - drug effects ; Case-Control Studies ; Chi-Square Distribution ; Citalopram - adverse effects ; Clinical pharmacology ; clinical research ; drug information ; epidemiology ; Female ; Humans ; Infant, Low Birth Weight ; Infant, Newborn ; Intensive Care Units, Neonatal ; Italy ; Live Birth ; Maternal Exposure ; Miscarriage ; Ontario ; Patient Admission ; Pregnancy ; Pregnancy Outcome ; Prospective Studies ; psychopharmacology ; Risk Assessment ; Risk Factors ; Serotonin Uptake Inhibitors - adverse effects ; Stillbirth ; Switzerland</subject><ispartof>Journal of clinical pharmacology, 2012-05, Vol.52 (5), p.766-770</ispartof><rights>2012 The Author(s)</rights><rights>2012 American College of Clinical Pharmacology</rights><rights>2012 SAGE Publications</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4954-11e728be071b2d3573182aa76c67314d2a69c55953cf23cd797ac51c7e9ffe5f3</citedby><cites>FETCH-LOGICAL-c4954-11e728be071b2d3573182aa76c67314d2a69c55953cf23cd797ac51c7e9ffe5f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22075232$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Klieger-Grossmann, Chagit</creatorcontrib><creatorcontrib>Weitzner, Brenda</creatorcontrib><creatorcontrib>Panchaud, Alice</creatorcontrib><creatorcontrib>Pistelli, Alessandra</creatorcontrib><creatorcontrib>Einarson, Thomas</creatorcontrib><creatorcontrib>Koren, Gideon</creatorcontrib><creatorcontrib>Einarson, Adrienne</creatorcontrib><title>Pregnancy Outcomes Following Use of Escitalopram: A Prospective Comparative Cohort Study</title><title>Journal of clinical pharmacology</title><addtitle>J Clin Pharmacol</addtitle><description>Escitalopram is a serotonin reuptake inhibitor prescribed for depression and anxiety. There is a paucity of information regarding safety in pregnancy. The objective of this study was to determine whether escitalopram is associated with an increased risk for major malformations or other adverse outcomes following use in pregnancy. The authors analyzed pregnancy outcomes in women exposed to escitalopram (n = 212) versus other antidepressants (n = 212) versus nonteratogenic exposures (n = 212) and compared the outcomes. Among the escitalopram exposures were 172 (81%) live births, 32 (15%) spontaneous abortions, 6 (2.8%) therapeutic abortions, 3 stillbirths (1.7%), and 3 major malformations (1.7%). The only significant differences among groups was the rate of low birth weight (<2500 g) and overall mean birth weight (P = .225). However, spontaneous abortion rates were higher in both antidepressant groups (15% and 16%) compared with controls (8.5%; P = .066). There were lower rates of live births (P = .006), lower overall birth weight (P < .001), and increased rates of low birth weight (<2500 g; P = .009) with escitalopram. Spontaneous abortion rates were nearly double in both antidepressant groups (15% and 16%) compared with controls (8.5%) but not significant (P = .066). Escitalopram does not appear to be associated with an increased risk for major malformations but appears to increase the risk for low birth weight, which was correlated with the increase in infants weighing <2500 g. In addition, the higher rates of spontaneous abortions in both antidepressant groups confirmed previous findings.</description><subject>Abnormalities, Drug-Induced - etiology</subject><subject>Abortion</subject><subject>Abortion, Spontaneous - chemically induced</subject><subject>Abortion, Therapeutic</subject><subject>Analysis of Variance</subject><subject>Antidepressants</subject><subject>Antidepressive Agents, Second-Generation - adverse effects</subject><subject>Birth weight</subject><subject>Birth Weight - drug effects</subject><subject>Case-Control Studies</subject><subject>Chi-Square Distribution</subject><subject>Citalopram - adverse effects</subject><subject>Clinical pharmacology</subject><subject>clinical research</subject><subject>drug information</subject><subject>epidemiology</subject><subject>Female</subject><subject>Humans</subject><subject>Infant, Low Birth Weight</subject><subject>Infant, Newborn</subject><subject>Intensive Care Units, Neonatal</subject><subject>Italy</subject><subject>Live Birth</subject><subject>Maternal Exposure</subject><subject>Miscarriage</subject><subject>Ontario</subject><subject>Patient Admission</subject><subject>Pregnancy</subject><subject>Pregnancy Outcome</subject><subject>Prospective Studies</subject><subject>psychopharmacology</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Serotonin Uptake Inhibitors - adverse effects</subject><subject>Stillbirth</subject><subject>Switzerland</subject><issn>0091-2700</issn><issn>1552-4604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqFUE1v1DAQtRAV3RbunFAkLlxCPY4dN9yqVbcFKrp8VHCzvM5kN60TBzvpsv8eRxsqVAlxsGasee_NvEfIS6BvAaQ8obQAJikF4FQIxp-QGcSa8pzyp2Q2jtNxfkiOQriNuJwLeEYOGaNSsIzNyI-lx3WrW7NLrofeuAZDsnDWum3drpObgImrkvNg6l5b13ndvEvOkqV3oUPT1_eYzF3Taa-nfuN8n3zth3L3nBxU2gZ8MdVjcrM4_za_TK-uL97Pz65SwwvBUwCU7HSFVMKKlZmQGZwyrWVu8tjykum8MEIUIjMVy0wpC6mNACOxqCoUVXZM3ux1O-9-Dhh61dTBoLW6RTcEBRQoyyDjNEJfP4LeusG38ToFksZ9jBd5RNE9ykSXwWOlOl832u-ilBpTV49Tj5RXk_CwarB8IPyJOQL4HrB1tkcf7uywRa82qG2_iXqU8qiXMgqMivhL44NRN59otcXdf-9QH-bLSyFg9JDuiUGv8S-X_zYw4evQ46-HRdrfqRiLFOr7pwv1ETj7zL4sFM9-A-q4tWg</recordid><startdate>201205</startdate><enddate>201205</enddate><creator>Klieger-Grossmann, Chagit</creator><creator>Weitzner, Brenda</creator><creator>Panchaud, Alice</creator><creator>Pistelli, Alessandra</creator><creator>Einarson, Thomas</creator><creator>Koren, Gideon</creator><creator>Einarson, Adrienne</creator><general>Blackwell Publishing Ltd</general><general>SAGE Publications</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201205</creationdate><title>Pregnancy Outcomes Following Use of Escitalopram: A Prospective Comparative Cohort Study</title><author>Klieger-Grossmann, Chagit ; Weitzner, Brenda ; Panchaud, Alice ; Pistelli, Alessandra ; Einarson, Thomas ; Koren, Gideon ; Einarson, Adrienne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4954-11e728be071b2d3573182aa76c67314d2a69c55953cf23cd797ac51c7e9ffe5f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Abnormalities, Drug-Induced - etiology</topic><topic>Abortion</topic><topic>Abortion, Spontaneous - chemically induced</topic><topic>Abortion, Therapeutic</topic><topic>Analysis of Variance</topic><topic>Antidepressants</topic><topic>Antidepressive Agents, Second-Generation - adverse effects</topic><topic>Birth weight</topic><topic>Birth Weight - drug effects</topic><topic>Case-Control Studies</topic><topic>Chi-Square Distribution</topic><topic>Citalopram - adverse effects</topic><topic>Clinical pharmacology</topic><topic>clinical research</topic><topic>drug information</topic><topic>epidemiology</topic><topic>Female</topic><topic>Humans</topic><topic>Infant, Low Birth Weight</topic><topic>Infant, Newborn</topic><topic>Intensive Care Units, Neonatal</topic><topic>Italy</topic><topic>Live Birth</topic><topic>Maternal Exposure</topic><topic>Miscarriage</topic><topic>Ontario</topic><topic>Patient Admission</topic><topic>Pregnancy</topic><topic>Pregnancy Outcome</topic><topic>Prospective Studies</topic><topic>psychopharmacology</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Serotonin Uptake Inhibitors - adverse effects</topic><topic>Stillbirth</topic><topic>Switzerland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Klieger-Grossmann, Chagit</creatorcontrib><creatorcontrib>Weitzner, Brenda</creatorcontrib><creatorcontrib>Panchaud, Alice</creatorcontrib><creatorcontrib>Pistelli, Alessandra</creatorcontrib><creatorcontrib>Einarson, Thomas</creatorcontrib><creatorcontrib>Koren, Gideon</creatorcontrib><creatorcontrib>Einarson, Adrienne</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Klieger-Grossmann, Chagit</au><au>Weitzner, Brenda</au><au>Panchaud, Alice</au><au>Pistelli, Alessandra</au><au>Einarson, Thomas</au><au>Koren, Gideon</au><au>Einarson, Adrienne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pregnancy Outcomes Following Use of Escitalopram: A Prospective Comparative Cohort Study</atitle><jtitle>Journal of clinical pharmacology</jtitle><addtitle>J Clin Pharmacol</addtitle><date>2012-05</date><risdate>2012</risdate><volume>52</volume><issue>5</issue><spage>766</spage><epage>770</epage><pages>766-770</pages><issn>0091-2700</issn><eissn>1552-4604</eissn><abstract>Escitalopram is a serotonin reuptake inhibitor prescribed for depression and anxiety. There is a paucity of information regarding safety in pregnancy. The objective of this study was to determine whether escitalopram is associated with an increased risk for major malformations or other adverse outcomes following use in pregnancy. The authors analyzed pregnancy outcomes in women exposed to escitalopram (n = 212) versus other antidepressants (n = 212) versus nonteratogenic exposures (n = 212) and compared the outcomes. Among the escitalopram exposures were 172 (81%) live births, 32 (15%) spontaneous abortions, 6 (2.8%) therapeutic abortions, 3 stillbirths (1.7%), and 3 major malformations (1.7%). The only significant differences among groups was the rate of low birth weight (<2500 g) and overall mean birth weight (P = .225). However, spontaneous abortion rates were higher in both antidepressant groups (15% and 16%) compared with controls (8.5%; P = .066). There were lower rates of live births (P = .006), lower overall birth weight (P < .001), and increased rates of low birth weight (<2500 g; P = .009) with escitalopram. Spontaneous abortion rates were nearly double in both antidepressant groups (15% and 16%) compared with controls (8.5%) but not significant (P = .066). Escitalopram does not appear to be associated with an increased risk for major malformations but appears to increase the risk for low birth weight, which was correlated with the increase in infants weighing <2500 g. In addition, the higher rates of spontaneous abortions in both antidepressant groups confirmed previous findings.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>22075232</pmid><doi>10.1177/0091270011405524</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-2700 |
| ispartof | Journal of clinical pharmacology, 2012-05, Vol.52 (5), p.766-770 |
| issn | 0091-2700 1552-4604 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1010231340 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Abnormalities, Drug-Induced - etiology Abortion Abortion, Spontaneous - chemically induced Abortion, Therapeutic Analysis of Variance Antidepressants Antidepressive Agents, Second-Generation - adverse effects Birth weight Birth Weight - drug effects Case-Control Studies Chi-Square Distribution Citalopram - adverse effects Clinical pharmacology clinical research drug information epidemiology Female Humans Infant, Low Birth Weight Infant, Newborn Intensive Care Units, Neonatal Italy Live Birth Maternal Exposure Miscarriage Ontario Patient Admission Pregnancy Pregnancy Outcome Prospective Studies psychopharmacology Risk Assessment Risk Factors Serotonin Uptake Inhibitors - adverse effects Stillbirth Switzerland |
| title | Pregnancy Outcomes Following Use of Escitalopram: A Prospective Comparative Cohort Study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A33%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pregnancy%20Outcomes%20Following%20Use%20of%20Escitalopram:%20A%20Prospective%20Comparative%20Cohort%20Study&rft.jtitle=Journal%20of%20clinical%20pharmacology&rft.au=Klieger-Grossmann,%20Chagit&rft.date=2012-05&rft.volume=52&rft.issue=5&rft.spage=766&rft.epage=770&rft.pages=766-770&rft.issn=0091-2700&rft.eissn=1552-4604&rft_id=info:doi/10.1177/0091270011405524&rft_dat=%3Cproquest_cross%3E1010231340%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4954-11e728be071b2d3573182aa76c67314d2a69c55953cf23cd797ac51c7e9ffe5f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1706732496&rft_id=info:pmid/22075232&rft_sage_id=10.1177_0091270011405524&rfr_iscdi=true |